Literature DB >> 8722437

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.

B R Davis1, J A Cutler, D J Gordon, C D Furberg, J T Wright, W C Cushman, R H Grimm, J LaRosa, P K Whelton, H M Perry, M H Alderman, C E Ford, S Oparil, C Francis, M Proschan, S Pressel, H R Black, C M Hawkins.   

Abstract

Are newer types of antihypertensive agents, which are currently more costly to purchase on average, as good or better than diuretics in reducing coronary heart disease incidence and progression? Will lowering LDL cholesterol in moderately hypercholesterolemic older individuals reduce the incidence of cardiovascular disease and total mortality? These important medical practice and public health questions are to be addressed by the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind trial in 40,000 high-risk hypertensive patients. ALLHAT is designed to determine whether the combined incidence of fatal coronary heart disease (CHD) and nonfatal myocardial infarction differs between persons randomized to diuretic (chlorthalidone) treatment and each of three alternative treatments--a calcium antagonist (amlodipine), an angiotensin converting enzyme inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin). ALLHAT also contains a randomized, open-label, lipid-lowering trial designed to determine whether lowering LDL cholesterol in 20,000 moderately hypercholesterolemic patients (a subset of the 40,000) with a 3-hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor, pravastatin, will reduce all-cause mortality compared to a control group receiving "usual care." ALLHAT's main eligibility criteria are: 1) age 55 or older; 2) systolic or diastolic hypertension; and 3) one or more additional risk factors for heart attack (eg, evidence of atherosclerotic disease or type II diabetes). For the lipid-lowering trial, participants must have an LDL cholesterol of 120 to 189 mg/dL (100 to 129 mg/dL for those with known CHD) and a triglyceride level below 350 mg/dL. The mean duration of treatment and follow-up is planned to be 6 years. Further features of the rationale, design, objectives, treatment program, and study organization of ALLHAT are described in this article.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8722437     DOI: 10.1016/0895-7061(96)00037-4

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  132 in total

1.  British guidelines on managing hypertension. Provide evidence, progress, and an occasional missed opportunity.

Authors:  B M Psaty; C D Furberg
Journal:  BMJ       Date:  1999-09-04

2.  Diagnosis and treatment of high blood pressure. New directions and new approaches: 1999 Canadian recommendations for management of hypertension.

Authors:  R J Petrella
Journal:  Can Fam Physician       Date:  2000-07       Impact factor: 3.275

Review 3.  Lessons learned from prematurely terminated clinical trials.

Authors:  D Sica
Journal:  Curr Hypertens Rep       Date:  2001-08       Impact factor: 5.369

Review 4.  Metabolic issues in the Antihypertensive and Lipid-Lowering Heart Attack Trial Study.

Authors:  Henry A Punzi; Connie F Punzi
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

5.  Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.

Authors:  Amy I Lynch; John H Eckfeldt; Barry R Davis; Charles E Ford; Eric Boerwinkle; Catherine Leiendecker-Foster; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2012-05       Impact factor: 2.089

6.  Comparative effectiveness research: an approach to avoiding "overgeneralized medicine".

Authors:  Mark Helfand; Sergio A Aguilar-Gaxiola; Harry P Selker
Journal:  Clin Transl Sci       Date:  2009-12       Impact factor: 4.689

7.  Bayesian regression model for recurrent event data with event-varying covariate effects and event effect.

Authors:  Li-An Lin; Sheng Luo; Barry R Davis
Journal:  J Appl Stat       Date:  2017-08-26       Impact factor: 1.404

8.  Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.

Authors:  Casper N Bang; Elsayed Z Soliman; Lara M Simpson; Barry R Davis; Richard B Devereux; Peter M Okin
Journal:  Am J Hypertens       Date:  2017-09-01       Impact factor: 2.689

9.  Longitudinal changes in dietary fat intake and associated changes in cardiovascular risk factors in adults with type 2 diabetes: the ACCORD trial.

Authors:  Julienne K Kirk; Timothy Craven; Edward W Lipkin; Jeffrey Katula; Carolyn Pedley; Patrick J O'Connor; Karen L Margolis
Journal:  Diabetes Res Clin Pract       Date:  2013-03-13       Impact factor: 5.602

10.  Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).

Authors:  Karen L Margolis; Kay Dunn; Lara M Simpson; Charles E Ford; Jeff D Williamson; David J Gordon; Paula T Einhorn; Jeffrey L Probstfield
Journal:  Am Heart J       Date:  2009-12       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.